London: GSK plc has received approval for Blenrep in the European Union (EU) for the treatment of adults with relapsed or ...

The question isn’t, “will you use AI?” The question is, “what kind of AI user do you want to be: driver or passenger?” ...

Alector’s 71% drop prompts a fresh look at its valuation, financials, and pipeline to gauge recovery prospects amid lingering ...

Hierarchical Reasoning Models (HRM) tackle complex reasoning tasks while being smaller, faster, and more data-efficient than large AI models.

When Sarah told her elderly mother about what she had found, she was horrified to hear that James had also been sexually ...

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

We thank Sara Osborne and colleagues for their interest in our trial.1 Ligelizumab phase 3 studies in patients with chronic spontaneous urticaria (CSU)1 were done with a study design and in ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...